GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Camacho RJ

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

  • Autores: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DMC, Vandamme AM, Vercauteren J, Wensing AMJ
  • Ano de Publicação: 2013
  • Journal: Retrovirology
  • Link: http://www.retrovirology.com/content/10/1/7

Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.
Ler mais

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

  • Autores: Abecasis A, Cabanas J, Camacho RJ, Gomes P, Libin P, Theys K, Van Laethem K
  • Ano de Publicação: 2015
  • Journal: Journal of Clinical Virology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/26305833

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty […]
Ler mais

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

  • Autores: Camacho RJ, Gomes P, Portuguese HIVRSG, Rhee SY, Theys K, Vandamme AM
  • Ano de Publicação: 2015
  • Journal: Clinical Microbiology and Infection
  • Link: http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(15)00299-2/fulltext%20

Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its clinical benefit for HIV-1 infected patients failing first-generation NNRTIs is largely undefined. This study quantified the extent of genotypic rilpivirine resistance in viral isolates from 1212 patients upon failure of efavirenz- or nevirapine-containing antiretroviral treatment, of whom more than respectively […]
Ler mais

Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

  • Autores: Bernatchez J, Camacho RJ, Covens K, De Wit S, Dekeersmaeker N, Götte M, Megens S, Theys K, Van Laethem K, Vandamme AM, Vinken L
  • Ano de Publicação: 2014
  • Journal: Acta Clinica Belgica
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25103592

The amino acid position 70 in HIV-1 reverse transcriptase (RT) plays an important role in nucleoside RT inhibitor (NRTI) resistance. K70R is part of the thymidine analog mutations, but also other amino acid changes have been associated with NRTI resistance, such as K70E and K70G. In this study, we investigated the in vivo selection of the HIV-1 RT mutations K70S and K70T and their in vitro effect on drug resistance and replication capacity.
Ler mais

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

  • Autores: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, Coughlan S, Frentz D, Griskevicius A, Grossman Z, Hamouda O, Horban A, Jørgensen LB, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Van de Vijver DA, Van Wijngaerden E, Vercauteren J, Wensing AMJ
  • Ano de Publicação: 2014
  • Journal: BMC Infectious Diseases
  • Link: http://www.biomedcentral.com/1471-2334/14/407

One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.
Ler mais

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013